The Global Triptorelin Market size is anticipated to reach USD 724.4 million by 2028 with a CAGR of 5.6% over the forecast period. Triptorelin is an injection peptide formulation that has been developed specifically to treat advanced metastatic prostate cancer. In addition, it is also used in the treatment of uterine fibroids, muscle tissue tumors in the uterus, endometriosis (endometrial tissue proliferation), the mucous membrane lining the uterine organ wall outside the reproductive tract prior to surgery or when surgery is not deemed necessary, as well as early puberty and female infertility (in vitro fertilization).
For the treatment of prostate cancer, additional triptorelin modalities such as triptorelin acetate, triptorelin pamoate, and triptorelin embonate are also used. Prostate cancer develops most of the time with elevated testosterone hormone levels. Triptorelin is a GnRH agonist intended to prevent testosterone flares. This helps lowers the level of testosterone and minimize prostate cancer progression.
It is expected that growing research and development of triptorelin for applications in different therapeutic indications by private manufacturers and research organizations will drive the growth of the triptorelin market. Different clinical trials are currently underway to extend the possible future use of triptorelin in breast cancer and human immunodeficiency virus (HIV). In addition, the widespread use of triptorelin in prostate cancer, cancer of the salivary gland, and central precocious puberty is expected to fuel market growth during the forecast period.
In addition, by introducing inorganic growth strategies, pharmaceutical manufacturers of triptorelin products are upgrading their product range to retain their market foothold. In August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business: Actavis Generics. Two leading generic companies with complementary strengths, research and development (R&D) capabilities, product pipeline and portfolio, organizational experience and regional footprint capabilities have thus been brought together with this strategic acquisition. Such acquisitions will play an important role in the growth of the global triptorelin market.
Prominent market players are also interested in expanding their product portfolio in different geographical areas. Arbor Pharmaceuticals, LLC and Debiopharm International SA, for example, made Triptodur (triptorelin) commercially available in the U.S. in October 2017, for pediatric patients two years and older diagnosed with central precocious puberty (CPP). In addition, in January 2016, both companies jointly announced the execution of a distribution agreement for the marketing and promotion of triptorelin 22.5 mg for central precocious puberty (CPP) in the US.
According to new indication, Decapeptyl (triptorelin) is used as an adjuvant treatment, along with tamoxifen or an aromatase inhibitor, for endocrine-responsive early-stage breast cancer in women at high risk of recurrence who are confirmed to be premenopausal after chemotherapy has been completed. This is expected to increase the growth revenue for the triptorelin industry over the forecast period. In addition, improved effectiveness and tolerability of triptorelin in suppressing the secretion of gonadotropin in prostate cancer and precocious puberty have increased its market adoption.
Global Triptorelin Market, By Product Type
In terms of product type, the global triptorelin market is categorized into triptorelin acetate, triptorelin pamoate, and triptorelin embonate. Among these, the triptorelin pamoate is one of the fastest-growing segments on account of its higher accessibility and wide range of usage.
Global Triptorelin Market, By Application
In terms of application, the global market is categorized into prostate cancer, salivary gland cancer, central precocious puberty, radical prostatectomy, and endometriosis. Among these, the prostate segment is likely to dominate the global market over the forecast period, as prostate cancer is the second most common cancer in men as well as the fourth most commonly occurring cancer overall.
Global Triptorelin Market, By End User
Based on end users, the market is segmented into hospitals pharmacy, retail pharmacies, and online pharmacy. The hospital pharmacy segment is to hold the highest share in the market over the forecast period due to improvements in practice with regard to pre-treatment considerations and appropriate monitoring during therapy.
Global Triptorelin Market, By Geographical Regions
North America had a leading position in the global market for triptorelin in terms of sales in 2018. The region's dominance is attributable to the growing prevalence of prostate cancer and salivary gland cancer, increasing occurrence of central precocious puberty among young patients under eight and nine years of age, and shifts in peoples’ lifestyle, eating habits, etc.
Key Market Developments:
Some Key Findings of the Global Triptorelin Market Report Include:
By End User
By Geographical Regions
Detailed scope covering all the major segments in the market
In line data validations to ensure data precision
Market recommendations supporting decision making processes
Round the clock analyst support to resolve your queries
Up to 15% additional free customization to meet your specific requirements